Biochemical investigation of rs1801282 variations in PPAR‐γ gene and its correlation with risk factors of diabetes mellitus in coronary artery disease. (31st May 2020)

• Record Type: Journal Article
• Authors: Rehman, Kanwal; Jabeen, Komal; Awan, Fazli Rabbi; Hussain, Misbah; Saddique, Muhammad Asim; Akash, Muhammad Sajid Hamid
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 47:Number 9(2020)
• Page Start: 1517
• Page End: 1529
• Publication Date: 2020-05-31
• Subjects: ARMS‐PCR -- cardiovascular diseases -- diabetes mellitus -- genotypes -- PPAR‐γ -- rs1801282; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.13339
• Languages: English
• ISSNs: 0305-1870

Abstract

Abstract: We aimed to investigate the association of single nucleotide polymorphism of Pro/Ala (rs1801282) in peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ) gene with risk factors of diabetes mellitus (DM) in cardiovascular disease (CVD) patients. We recruited 244 participants from Faisalabad Institute of Cardiology and Department of Cardiology, Sargodha District Head Quarter Teaching Hospital, Pakistan. Out of 244 participants, 144 cases were CVD patients and 100 were healthy controls. CVD patients were further divided into 111 coronary artery disease (CAD) and 33 cardiomyopathy (CMP) patients. Assessment of variant specific polymorphism/mutation of Pro/Pro and Pro/Ala genotypes was done through amplification refractory mutation system polymerase chain reaction (ARMS‐PCR). Further, serum biomarkers were measured to investigate the association among risk factors of DM and Pro/Ala polymorphism in PPAR‐γ gene. About 31.5% Pro/Ala genotype was found in CVD patients out of which 22.5% were CAD patients and 9% were CMP patients. As a result, obesity, hypertension and smoking (35%, 23%, 21%, respectively) were observed to be the most critical risk factors accompanying Pro/Ala mutation in PPAR‐γ particularly in CAD patients as compared to that in CMP patients. A similar pattern of association was observed among the elevated levels of glucose, cholesterol, triglyceride and ALT with Pro/Ala mutation in CAD patients. Further, CAD patients using ACE inhibitors (18%) and β‐blockers (13%) were found to be the carriers of Pro/Ala genotype and also showed significant increase in glucose level. This study suggests that hyperglycaemia in CAD patients particularly obese, smokers and hypertensives having Pro/Ala polymorphism in PPAR‐γ gene are at high risk of developing DM as clearly observed by hyperglycaemia in CAD patients.